SYSTEMATIC REVIEW article
Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1609071
Outcomes of Coronary Revascularization in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review
Provisionally accepted
Jacob J Gries1Hafeez Ul Hassan Virk2
Zhen Wang3Mahboob Alam4
Samin K Sharma5
Markus Strauß6*Chayakrit Krittanawong7- 1Geisinger Medical Center, Danville, Pennsylvania, United States
- 2University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- 3Mayo Clinic, Rochester, Minnesota, United States
- 4Baylor College of Medicine, Houston, Texas, United States
- 5Mount Sinai Hospital, New York, New York, United States
- 6University Muenster, Münster, Germany
- 7HumanX, Delaware, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduc.on. A growing amount of evidence suggests that MASLD may independently increase the risk of coronary artery disease and acute coronary syndrome, thus necessita.ng revasculariza.on interven.ons like percutaneous coronary interven.on (PCI) and coronary artery bypass graFing (CABG) [2,3]. However, a limited number of studies have evaluated the impact of MASLD on the outcomes of these interven.ons.Methods. A comprehensive search of the PubMed/MEDLINE and Embase databases was conducted to iden.fy relevant studies from August 2015 to August 2025 using a combina.on of Medical Subject Headings (MeSH) terms and text words related to MASLD and cardiovascular revasculariza.on.Results. Two hundred nineteen papers from the PubMed/MEDLINE and Embase databases were reviewed. Six met the inclusion criteria (Figure 1). Five studies covered PCI, and one covered CABG. Supplemental informa.on was added using targeted PubMed/MEDLINE searches.Conclusions. MASLD may pose an increased risk of in-hospital and long-term mortality following PCI. Risks for cardiogenic shock, cardiac arrest, in-stent thrombosis, gastrointes.nal bleeding, or invasive mechanical ven.la.on following PCI may also be increased. Further studies are needed to determine the op.mal coronary revasculariza.on method and post-revasculariza.on medical therapy for pa.ents with MASLD.
Keywords: coronary heart disaese, MASLD, Coronary revascularisation, Liver disease, Coronary Disease, Metabolic dysfunction associated fatty liver disease (MASLD)
Received: 09 Apr 2025; Accepted: 22 Jul 2025.
Copyright: © 2025 Gries, Hassan Virk, Wang, Alam, Sharma, Strauß and Krittanawong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Markus Strauß, University Muenster, Münster, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.